Headquartered in Brisbane, CA Fiscal year ends December NASDAQ: CDNA caredx.com
CareDx, Inc. is a precision medicine diagnostics company focused on transplant, specialty oncology, and cell therapy. The company provides non-invasive longitudinal molecular biomarker testing, digital health solutions, and patient support services. Its core Testing Services portfolio includes AlloSure (donor-derived cell-free DNA testing for transplant surveillance), AlloMap (gene expression profiling for heart transplant monitoring), and NavDx (a tumor-informed circulating tumor DNA assay acquired through Naveris for specialty oncology). CareDx also operates CareDx Pharmacy and offers patient and digital solutions that support transplant monitoring workflows. The company recently divested its Lab Products business to Eurobio Scientific and acquired Naveris to expand into specialty oncology and cell therapy diagnostics. CareDx's pipeline programs include AlloHeme for hematopoietic cell transplant monitoring and HistoMap Kidney for molecular assessment of kidney transplant biopsies. The company trades on Nasdaq under the ticker CDNA. Updated
These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, they are not penny stocks with…
24/7 Wall St. looks at some big analyst calls that we have seen so far on Tuesday, including Apple, Array Technologies, CareDx and Vertex Pharmaceuticals.
CareDx, Inc. is a precision medicine diagnostics company focused on transplant, specialty oncology, and cell therapy. The company provides non-invasive longitudinal molecular biomarker testing, digital health solutions, and patient support services.
The Wall Street consensus 12-month price target for CDNA is $58.83.
